Abstract: The present invention discloses an in vitro method for obtaining DNA methylation biomarkers as exquisite DNA methylation positions in the human genome (i.e., CGIDs) that predict cervical cancer especially at as yet inaccessible early stages by examining progression of “categorical” DNA methylation alterations in three stages of premalignant lesions (cervical intraepithelial neoplasia (CIN)), progressing from CIN1 to CIN3. The present invention discloses combinations of CGIDs for detecting with high specificity and sensitivity cervical cancer by measuring their DNA methylation status and deriving a “methylation score”, which is useful as a biomarker for cervical cancer. Also disclosed are kits for predicting cervical cancer using such CGIDs using multiplexed next generation sequencing methylation assays, pyrosequencing assays and methylation specific PCR.

Abstract: The present invention relates to method for calculating biological age of a subject and across multiple subjects by performing polygenic DNA methylation on biomarkers which comprise measuring the methylation status of 13 CG sites positioned in a putative antisense region to ElovL2 gene, ElovL2 AS1 region. Further, the present invention provides a computer-implemented method for providing recommendations for lifestyle changes in form of a self-learning “ecosystem” for lifestyle management of biological aging using a novel measurement of the DNA methylation clock as a continuous dynamic outcome. The present invention also relates to combination of DNA methylation biomarkers for calculating biological age, a kit for determining the biological age. Further, the present invention discloses the use of the disclosed methods for calculating biological age in a method of assessing the effect of the effect of a biological intervention and in a method of screening for an anti-ageing agent.

Abstract: The present invention discloses an in vitro method for obtaining DNA methylation biomarkers as exquisite DNA methylation positions in the human genome (i.e., CGIDs) that predict cervical cancer especially at as yet inaccessible early stages by examining progression of “categorical” DNA methylation alterations in three stages of premalignant lesions (cervical intraepithelial neoplasia (CIN)), progressing from CIN1 to CIN3. The present invention discloses combinations of CGIDs for detecting with high specificity and sensitivity cervical cancer by measuring their DNA methylation status and deriving a “methylation score”, which is useful as a biomarker for cervical cancer. Also disclosed are kits for predicting cervical cancer using such CGIDs using multiplexed next generation sequencing methylation assays, pyrosequencing assays and methylation specific PCR.

Abstract: A “binary-categorical differentiation (BCD)” method for finding a combination of a small number (2-10) of exquisite DNA methylation positions in the human genome (CG IDs) for detecting cancer in DNA in biological material derived from a patient such as plasma, saliva, urine, feces, tissue biopsy, tissue swabs and tissue smears (such as pup smears) and distinguish it from other tissue cell free DNA and blood cells DNA. Another method for detecting tissue of origin of tumor DNA uses a combination of small number of unique DNA methylation positions in the human genome (CG IDs). Various novel combinations of CG IDs derived from tumor DNA are disclosed for detecting with high specificity and sensitivity a hepatocellular carcinoma (HCC), b. lung cancer, c. prostate cancer, d. breast cancer, e. colorectal cancer, f. pancreatic cancer, g. brain cancer (glioblastoma), h. gastric cancer i. ovarian cancer, j. cervical cancer k. head and neck squamous cell carcinoma (HNSC), l. esophageal cancer m. bladder cancer, n.